ArticleslgStudy

science

MVA85A

MVA85A is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand MVA85A rather than just read about it. In short: MVA85A (modified vaccinia Ankara 85A) was a candidate vaccine against tuberculosis developed by researchers led by Professor Helen McShane at Oxford University. It is a viral vector vaccine and consists of an MVA virus engineered to express the 85A antigen once it infects a host cell. 85A is a cell-wall protein of the tuberculosis bacillus.

Key takeaways

  • MVA85A belongs to science; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect MVA85A to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of MVA85A from memory before moving on to harder problems.

Reference excerpt

MVA85A (modified vaccinia Ankara 85A) was a candidate vaccine against tuberculosis developed by researchers led by Professor Helen McShane at Oxford University. It is a viral vector vaccine and consists of an MVA virus engineered to express the 85A antigen once it infects a host cell. 85A is a cell-wall protein of the tuberculosis bacillus. This vaccine was believed to produce higher levels of long-lasting cellular immunity when used together with the older TB vaccine BCG. Phase I clinical trials were completed in 2008 and then phase II clinical trials took place in South Africa. A number of efficacy trials ran in parallel from 2009 to 2019. Results released in February 2013 were described as "disappointing", showing only a statistically insignificant prevention rate in infants. A summary of animal studies published in 2015 cast doubt on the efficacy of the vaccine. In 2018, a BMJ investigation raised concerns about the ethics of an efficacy trial in South African infants, particularly because of results from earlier animal trials such as a study with macaques at Porton Down. One response argued that 14 prior human trials showed a safety signal, that regulators were aware of the primate trial and decided to continue, and that three subsequent investigations found no evidence of wrong-doing. Another response by Ian Orme questioned the critique of animal models. A Cochrane review in 2019 concluded that MVA85A is safe, however it is not effective in preventing TB infection either on its own or in combination with BCG.

References

External links New TB vaccine shown to be safe

Worked examples

Example 1 — a first encounter with MVA85A

Start with the simplest possible case. Write down what MVA85A claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to MVA85A before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about MVA85A ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of MVA85A

In research
MVA85A appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses MVA85A in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
MVA85A is common in secondary-school and first-year university syllabi. It links to neighbouring topics Tuberculosis vaccines, Vaccine stubs, so understanding it makes those chapters shorter.
In everyday life
Look for MVA85A outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study MVA85A in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what MVA85A means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain MVA85A out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is MVA85A in simple terms?

MVA85A (modified vaccinia Ankara 85A) was a candidate vaccine against tuberculosis developed by researchers led by Professor Helen McShane at Oxford University. It is a viral vector vaccine and consists of an MVA virus engineered to express the 85A antigen once it infects a host cell. 85A is a cell…

Why does MVA85A matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study MVA85A?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on MVA85A.

Tags

  • Tuberculosis vaccines
  • Vaccine stubs

Keep exploring